Yuqing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuqing Zhou has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chencheng Wang
School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang 212013, Jiangsu Province, PR China
1 shared publication - Cheng Ding
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine
1 shared publication - Chenyang Huang
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
1 shared publication - Hongliang Wang
Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Jie Wu
State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
1 shared publication - Jingshen Wang
Division of Biostatistics, University of California Berkeley
1 shared publication
Latest Publications
- Open Access
Inference on the Best Policies with Many Covariates
Understanding the impact of the most effective policies or treatments on a response variable of interest is desirable in many empirical works in economics, statistics and other disciplines. Due to the widespread winner's curse phenomenon, conventional statistical inference assuming that the top policies are chosen independent of the random sample may lead to overly optimistic evaluations of the best policies. In recent years, given the increased availability of large datasets, such an issue can be further complicated when researchers include many covariates to estimate the policy or treatment effects in an attempt to control for potential confounders. In this manuscript, to simultaneously address the above-mentioned issues, we propose a resampling-based procedure that not only lifts the winner's curse in evaluating the best policies observed in a random sample, but also is robust to the presence of many covariates. The proposed inference procedure yields accurate point estimates and valid frequentist confidence intervals that achieve the exact nominal level as the sample size goes to infinity for multiple best policy effect sizes. We illustrate the finite-sample performance of our approach through Monte Carlo experiments and two empirical studies, evaluating the most effective policies in charitable giving and the most beneficial group of workers in the National Supported Work program.
Open AccessInference on the Best Policies with Many Covariates
Understanding the impact of the most effective policies or treatments on a response variable of interest is desirable in many empirical works in economics, statistics and other disciplines. Due to the widespread winner's curse phenomenon, conventional statistical inference assuming that the top policies are chosen independent of the random sample may lead to overly optimistic evaluations of the best policies. In recent years, given the increased availability of large datasets, such an issue can be further complicated when researchers include many covariates to estimate the policy or treatment effects in an attempt to control for potential confounders. In this manuscript, to simultaneously address the above-mentioned issues, we propose a resampling-based procedure that not only lifts the winner's curse in evaluating the best policies observed in a random sample, but also is robust to the presence of many covariates. The proposed inference procedure yields accurate point estimates and valid frequentist confidence intervals that achieve the exact nominal level as the sample size goes to infinity for multiple best policy effect sizes. We illustrate the finite-sample performance of our approach through Monte Carlo experiments and two empirical studies, evaluating the most effective policies in charitable giving and the most beneficial group of workers in the National Supported Work program.
- 1 November 2019
- Published by Wiley in Liver International
- Vol. 40 (2) , 298-307
Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030
Background & Aims: Trends in long‐term mortality rates for viral hepatitis in East and Southeast Asia have been rarely reported. The aim of our study was to explore the long‐term trends in viral hepatitis mortality rates in East and Southeast Asian countries between 1987 and 2015 and provide predictions of mortality to 2030.Methods: We obtained viral hepatitis mortality data from the WHO Mortality Database for six East and Southeast Asian countries between 1987 and 2015. We produced choropleth maps of viral hepatitis mortality rates in 1987 and 2015 in East and Southeast Asia to illustrate geographic variations. We made predictions of mortality rates for each included country until the year 2030 using a series of joinpoint models.Results: Viral hepatitis mortality rates declined in China (the average annual percent change (AAPC) = −5.1%, 95% CI: −7.5, −2.6), Singapore (AAPC = −5.4%, 95% CI: −7.5, −3.2), and the Philippines (AAPC = −3.4%, 95% CI: −4.9, −1.8). In contrast, Japan, the Republic of Korea, and Malaysia have experienced increasing trends in mortality rates, followed by decreasing trends. Our predictions indicate that all countries will experience slight to moderate downward trends until 2030.Conclusion: Favourable decreasing trends have been noted in East and Southeast Asian countries, which may not only inform the control and management of viral hepatitis in this region but also guide the prevention of viral hepatitis deaths in another region with a similar viral hepatitis epidemic.
- 1 November 2019
- Published by Wiley in Liver International
- Vol. 40 (2) , 298-307
Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030
Background & Aims: Trends in long‐term mortality rates for viral hepatitis in East and Southeast Asia have been rarely reported. The aim of our study was to explore the long‐term trends in viral hepatitis mortality rates in East and Southeast Asian countries between 1987 and 2015 and provide predictions of mortality to 2030.Methods: We obtained viral hepatitis mortality data from the WHO Mortality Database for six East and Southeast Asian countries between 1987 and 2015. We produced choropleth maps of viral hepatitis mortality rates in 1987 and 2015 in East and Southeast Asia to illustrate geographic variations. We made predictions of mortality rates for each included country until the year 2030 using a series of joinpoint models.Results: Viral hepatitis mortality rates declined in China (the average annual percent change (AAPC) = −5.1%, 95% CI: −7.5, −2.6), Singapore (AAPC = −5.4%, 95% CI: −7.5, −3.2), and the Philippines (AAPC = −3.4%, 95% CI: −4.9, −1.8). In contrast, Japan, the Republic of Korea, and Malaysia have experienced increasing trends in mortality rates, followed by decreasing trends. Our predictions indicate that all countries will experience slight to moderate downward trends until 2030.Conclusion: Favourable decreasing trends have been noted in East and Southeast Asian countries, which may not only inform the control and management of viral hepatitis in this region but also guide the prevention of viral hepatitis deaths in another region with a similar viral hepatitis epidemic.